title: Antitumor activity of recombinant RGD-IFN-α2a-core fusion protein in vitro.
abstract: Interferon (IFN) regulates immune responses and antitumor activity. Arginine-glycine-aspartic acid (RGD) peptides can specifically bind to integrin αvβ3, a transmembrane receptor that is highly expressed on the surface of various cancer cells. In this study, we expressed recombinant RGD-IFN-α2a-core fusion proteins and assessed their antitumor activity in vitro. Two RGD-IFN-α2a-core fusion proteins and a negative control protein were expressed in vitro. These two RGD-IFN-α2a-core fusion proteins could bind the tumor cell surface specifically and did not bind to normal cells. RGD-IFN-α2a-core fusion protein treatment of tumor cells significantly reduced cell viability and induced apoptosis in a dose-dependent manner. At the 'mRNA' level, both proteins could upregulate CASP3 expression. These data indicate that both laboratory-engineered RGD-IFN-α2a-core fusion proteins could bind the surface of tumor cells and induce apoptosis in vitro. Further studies will investigate the in-vivo antitumor activities of the RGD-IFN-α2a-core fusion proteins.
authors.affiliation: aDepartment of Nuclear Medicine, School of Basic Medical Sciences bZhejiang Provincial Key Lab of Medical Genetics cZhejiang Provincial Key Lab for Technology and Application of Model Organisms dInstitute of Medical Virology, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou eThe First Hospital of Changsha City, Kaifu District, Changsha, China.
authors.forename: Zhengwei
authors.initials: Z
authors.lastname: Wen
authors.forename: Qunying
authors.initials: Q
authors.lastname: Jia
authors.forename: Xiaojuan
authors.initials: X
authors.lastname: Kang
authors.forename: Yongliang
authors.initials: Y
authors.lastname: Lou
authors.forename: Lilin
authors.initials: L
authors.lastname: Zou
authors.forename: Jifeng
authors.initials: J
authors.lastname: Yang
authors.forename: Jimin
authors.initials: J
authors.lastname: Gao
authors.forename: Liping
authors.initials: L
authors.lastname: Han
authors.forename: Xiang
authors.initials: X
authors.lastname: Li
mesh_terms: D000072283:A549 Cells; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D045744:Cell Line, Tumor; D003001:Cloning, Molecular; D003110:Colonic Neoplasms / Q000188:drug therapy; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D016898:Interferon-alpha / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology*; D008175:Lung Neoplasms / Q000188:drug therapy; D009842:Oligopeptides / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology*; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D009842:Oligopeptides; D011993:Recombinant Fusion Proteins; C047981:arginyl-glycyl-aspartic acid